350 studies found for:    leukemia AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Terminated
Has Results
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
Intervention: Drug: deferoxamine
22 Active, not recruiting B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
Condition: Chronic Lymphocytic Leukemia
Intervention:
23 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
24 Recruiting Delayed Effects of Treatment in Cancer Survivors (DETECS)
Conditions: Breast Cancer;   Leukemia;   Lymphoma;   Gynecologic Cancer
Intervention:
25 Completed Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Gleevec
26 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
27 Completed
Has Results
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WT1 Peptide Vaccine
28 Recruiting Phase I Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR PBL
29 Recruiting Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors
Conditions: Chronic Myeloid Leukemia;   Pregnancy
Intervention:
30 Terminated Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Drug: moxifloxacin hydrochloride;   Drug: Placebo
31 Completed Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Condition: Human T-Lymphoma Virus Type I
Intervention:
32 Active, not recruiting Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
33 Terminated Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Cardiac Toxicity;   Inflammatory Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
34 Active, not recruiting B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression
Condition: Chronic Lymphocytic Leukemia
Intervention:
35 Active, not recruiting Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
36 Active, not recruiting Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
37 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
38 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: doxorubicin hydrochloride;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Other: laboratory biomarker analysis
39 Completed Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
Condition: Leukemia
Intervention: Drug: docetaxel
40 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years